This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

cinacalcet (Mimpara™)

Reference No. 3294

Publication date:

Appraisal information

cinacalcet (Mimpara™) 30 mg film-coated tablet
cinacalcet (Mimpara™) 60 mg film-coated tablet
cinacalcet (Mimpara™) 90 mg film-coated tablet
cinacalcet (Mimpara™) 1 mg granules
cinacalcet (Mimpara™) 5 mg granules
cinacalcet (Mimpara™) 2.5 mg granules

Company: Amgen Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/11/2017

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cinacalcet (Mimpara™) cannot be endorsed for use within NHS Wales for the treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.
Statement of Advice (SOA)